CLL - FOI Response Register

1. How many newly diagnosed patients with chronic lymphocytic Leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Nil

2. How many of these newly diagnosed patients with CLL received chemo immunotherapy (CIT) as first-line treatment?

Nil

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab 

Nil

3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

• FCR (fludarabine + cyclophosphamide + rituximab)
• FR (fludarabine + rituximab)
• BR (bendamustine + rituximab)
• Bendamustine monotherapy
• RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
• Obinutuzumab ± chlorambucil
• Rituximab + chlorambucil
• Ofatumumab
• Other – please specify

Nil

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window 

Nil to all